Karl Deisseroth, Peter Hegemann, and Georg Nagel win 2026 Nobel Prize in Physiology or Medicine for optogenetics

The 2026 Nobel Prize in Physiology or Medicine has been awarded jointly to Karl Deisseroth, Peter Hegemann, and Georg Nagel for discovering channelrhodopsin and developing optogenetics.

Announced by the Nobel Committee, the award recognises their pioneering work in using light to control living neurons. The laureates share a prize of 12 million Swedish kronor, equivalent to approximately $1.2 million USD.

Optogenetics bridges biology and engineering to map complex neural circuits. The technique relies on light-sensitive proteins called opsins, which are introduced into specific cells to act as microscopic switches that turn cellular activity on or off when exposed to light.

Before this development, researchers depended on crude methods such as electrical stimulation, which frequently activated multiple neighboring neurons simultaneously and hindered precise observation. Optogenetics allows scientists to target specific groups of neurons with high accuracy, functioning similarly to controlling an individual light bulb rather than powering off an entire building.

This precision enables researchers to investigate complex neurological questions, including identifying which neurons trigger seizures, drive addiction, store memories, or contribute to depression and chronic pain. By toggling specific cells and observing behavioral outcomes, scientists can establish clearer cause-and-effect relationships within brain activity.

The technology holds significant medical potential for conditions involving abnormal neural circuit activity, such as Parkinson’s disease and epilepsy. By identifying malfunctioning cells, future treatments could target specific circuits far more precisely than conventional methods allow.

In ophthalmology, researchers are testing optogenetic principles to address inherited retinal diseases where photoreceptor cells are destroyed. By introducing light-sensitive proteins into surviving retinal cells, early human studies indicate the approach can generate visual perception in patients with severe retinal degeneration, offering a potential new light-detection system for damaged nervous systems.

Beyond neurology and ophthalmology, scientists are studying light-controlled biological systems across immune cells, cellular signaling, and targeted drug delivery. These applications aim to activate medicines or biological processes exclusively at diseased sites, minimizing impact on healthy cells.